Data Support Safe Interaction of Darolutamide and Cabazitaxel in mCRPC

Article

Unlike with enzalutamide, it appears darolutamide does not affect systemic exposure of cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Effects of darolutamide (Nubeqa) do not appear to influence systemic exposure of cabazitaxel (Jevtana), justifying their potential future use in combination for the treatment of metastatic castration-resistant prostate cancer, according to data presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.1

In describing the background for the study, the authors explained that “there is mounting evidence that addition of an androgen receptor signaling inhibitor improves taxane efficacy in prostate cancer.”2,3 One of the studies spotlighted showed that simultaneous blocking of androgen receptor signaling with enzalutamide (Xtandi) improves efficacy of cabazitaxel, with the authors writing, “These findings support clinical studies that combine AR targeted inhibitors with cabazitaxel in CRPC.”2

However, the authors of the current study noted in their poster, “Drug-drug interactions may hamper these beneficial effects.”

For the current study, investigators led by Stefan Buck, MD, PhD, of Erasmus MC Cancer Institute in Rotterdam, the Netherlands, evaluated patients with metastatic castration-resistant prostate cancer who were treated with cabazitaxel alone (20 mg/m2 every 3 weeks) and with cabazitaxel and darolutamide (600 mg twice daily) for 6 weeks. They measured cabazitaxel exposure on day 1 and after 6 and 12 weeks of treatment with darolutamide using area under the curve from 0 to 24 hours (AUC0-24h).

The investigators found that cabazitaxel systemic exposure in 18 patients after 6 weeks of treatment with darolutamide was not significantly different compared with prior darolutamide treatment (AUC0-24h, –4%; 95% CI, –19 –to 13%; P = .58). In addition, following 12 weeks of treatment with darolutamide, cabazitaxel systemic exposure was unaltered (AUC0-24h, 4%; 95% CI, –10 to 20%; P = .54).

“Darolutamide, unlike enzalutamide, does not affect cabazitaxel systemic exposure, justifying their use in combination,” the authors wrote in their poster. For future directions for research, they suggested “a randomized phase 2 study on cabazitaxel plus or minus darolutamide in patients previously treated with a novel androgen receptor signaling agent.”

References

  1. Buck S, Guchelaar NAD, de Bruijn P, et al. Influence of darolutamide on cabazitaxel systemic exposure. J Clin Oncol. 2022;40(suppl 16):5038. doi:10.1200/JCO.2022.40.16_suppl.5038
  2. Smith MR, Hussain M, Saad F. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132-1142. doi:10.1056/NEJMoa2119115
  3. Mout L, van Royen ME, de Ridder C, et al. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. EBioMedicine. 2021;73:103681. doi:10.1016/j.ebiom.2021.103681

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content